MariMed Secures Exclusive Global Licensing, Distribution for Vitiprints Revolutionary, Proprietary Cannabis Printing Technology - Wealthy Venture Capitalist

MariMed Secures Exclusive Global Licensing, Distribution for Vitiprints Revolutionary, Proprietary Cannabis Printing Technology

● Platform creates new category of precision dosed dissolvable cannabis products at efficiencies unsurpassed in the industry.

● Cannabis-infused medium enables rapid delivery sublingually, transdermally, or in liquid.

● The Vitiprints platform efficiently layers ingredients and graphic design, offering endless options for amazing customer products, experiences.

NEWTON, Mass., NEW YORK, Aug. 02, 2018 (GLOBE NEWSWIRE) — MariMed Inc., (OTCQB:MRMD) today announced that it has signed an exclusive global licensing agreement with Vitiprints™ for the worldwide production and distribution rights in all existing and future legal cannabis markets. The agreement extends to all cannabis products made using Vitiprints’ proprietary technology, including liquid ingredient formulation, printing process, and the resulting array of dissolvable products.

“Our exclusive agreement with Vitiprints puts MariMed on the forefront of precision-dosed branded cannabis products and technology that will, above all, delight consumers with a revolutionary product category and experience,” said Robert Fireman, MariMed CEO. “This innovative technology enables creation of infused cannabis products which can be specifically designed for dosage, flavor, and supplements to achieve the desired effect or result. These products can be manufactured at speeds and efficiencies that will create cost savings for producers and consumers, while generating significant incremental revenue streams for MariMed from sales and sublicensing agreements.”

The patent-pending Vitiprints technology – a first for the cannabis industry — is already under development for consumer consumption in other industries. For MariMed, the platform combines multiple layers of marijuana ingredients, such as cannabinoids, terpenes, graphic design elements and other ingredients, into a paper-thin low-calorie product that is delivered sublingually, transdermally, or by drinking when dissolved in any liquid.  The product can be used to create its own beverage or tea or as an enhancement to other beverages. Achieving total control over the ingredient layers, the platform further enables precision dosing and fast absorption, without the additional fillers commonly found in cannabis and nutraceutical products. This product transports easily in purses, pockets, and wallets with seamless discretion and convenience.

“MariMed’s management immediately recognized the advantages Vitiprints offered for flexibility in production, dosage, and design and how this is a game changing array of products for the cannabis industry,” stated Andrew Ferber, Co-founder and CEO. “We chose to partner with MariMed from the myriad of cannabis companies because their strategic vision and goals are aligned with ours and we have confidence their extensive experience as multi-state operators with a growing national distribution network will help us quickly penetrate the U.S. and international cannabis markets. We will continue to work with MariMed to develop new innovative products for this emerging industry.”

MariMed expects to complete test marketing of the dissolvable product sets in a MariMed-managed facility within 90 days, then launch in legal states across the country, and finally expand worldwide via sublicense agreements with qualified manufacturers and distributors. Products will be available on shelves as early as the end of Q4 2018.

“Vitiprints is ideally suited and ‘future proof’ against the widely differing and ever-changing cannabis regulations regarding dosing, formulation and appearance, enabling instant modification via the user interface versus a complete product redesign,” said Ryan Crandall, MariMed VP of Brand and Licensing. “Furthermore, we are able to engage customers by using printed design layers as a touch point into our customer education and engagement portal, in turn generating loyalty and feedback. It’s a dream come true for product development and marketing teams,” Crandall added.

Follow MariMed and post on social media with the hash tag #MedicatedByMarimed:

Twitter: @MariMedInc
Facebook: @MariMedInc
Instagram: MariMedInc
YouTube: MariMedInc

# # #

About MariMed Inc.:
MariMed is a multi-state professional cannabis organization that develops, owns and manages cannabis facilities and branded products lines. MariMed’s team has developed state-of-the-art regulatory-compliant facilities in DE, IL, NV, MD, MA, and RI which are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. In addition, MariMed is on the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries. MariMed Inc. is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com). For additional information, visit www.MariMedAdvisors.com

About Vitiprints: 
Vitiprints™ is a company founded on its proprietary and patent pending print technologies that were developed to enhance the health and well-being of people worldwide by printing pure ingredients with highly accurate dosing of high-quality nutritional supplements, OTC ingredients, cannabis products, and flavorings in soluble vehicle systems. Printing allows for enormous economy of scale cost reductions while eliminating the need for costly fillers, bottles, packaging and related shipping costs while maintaining tight tolerances for controlled ingredients, all delivered in a 2D edible print-based product. The proprietary track and trace printing system will allow for every product to have cradle to grave accountability and is accessible to every customer.

Forward Looking Statements:

This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement and changes in the economic environment. Additional risk factors are included in the Company’s public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “planned, “estimated,” “preparing,” “potential,” “expected” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

Contacts:
For MariMed
Business Development
Jon Levine, CFO, MariMed
info@MariMedAdvisors.com
781-559-8713

Investors
Tyler Troup, Circadian Group
tyler@circadian-group.com
+1 (866) 950 8300

Media
Julie Shepherd, Accentuate PR
Julie@accentuatepr.com
847-275-3643

For Vitiprints
Business Development
Andrew Ferber, Partner
aferber@vitiprintsllc.com
646-591-4343

Primary Logo

Source: MariMed Inc

Leave a Reply

Your email address will not be published. Required fields are marked *

pour la musculation tamoxifen buylivraison anonyme, prix favorable As a rule, the infection occurs during penetrative sexual intercourse buy metronidazole no prescription moist environment and can remain viable. cialis 20mg rezeptfreider Wirkstoff des Arzneimittels wird nicht verlassen, Zweifel an der Wirksamkeit der Pillen ein bewährtes Medikament zur Behandlung von BPH in einer Dosierung von 10 mg, die Möglichkeit gibt, ein neues Potential des Penis, um zu versuchen buy Retin AThis drug will no doubt help to solve the problem with acne in young people from 16 years, thanks to the active ingredient of this cream you will experience relief, people will stop laughing at you Diagnosticare la causa della disfunzione erettilecomprar cilaiscosì spesso il trattamento può comportare molteplici tecniche. Comprar cialis en línea

Wealthy Venture Capitalist